Carbohydrate (i.e., Saccharide Radical Containing) Doai Patents (Class 514/23)
  • Patent number: 10293054
    Abstract: In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 21, 2019
    Assignee: LivePet, LLC
    Inventors: Ian Mitchell, Ayyappan Subbiah, Daniel David Bensimon
  • Patent number: 10292635
    Abstract: A method of assessing the likelihood that an individual has impulse control disorder. The individual is provided with an actuator, and instructed to actuate the actuator as an acknowledgement of when the individual has completed a reward task. Actuation of the actuator is monitored and recorded. An automated diagnosis of ICD is produced and output, wherein a greater degree of actuation of the actuator by the individual is taken to indicate a greater likelihood that the individual has impulse control disorder.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: May 21, 2019
    Assignee: Global Kinetics Pty Ltd
    Inventors: Robert Irwin Griffiths, Malcolm Kenneth Home, Andrew H. Evans
  • Patent number: 10292382
    Abstract: Methods and processes for cryopreservation and direct cell thawing and seeding or suspension after cryopreservation, including methods that eliminate the necessity of post-thaw wash, spin, and frequent practice of performing a cell count. Cell compositions and no-spin cell products produced using the methods are also described.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 21, 2019
    Assignee: Biopredic International Sarl
    Inventors: Belkacem Bouaita, Sandrine Camus, Nathalie Rougier, Ruo Ya Li, Christophe Chesne, David M. Steen
  • Patent number: 10285969
    Abstract: The present invention provides a mangiferin-6-O-berberine salt and a preparation method thereof, and further provides a use of the mangiferin-6-O-berberine salt for the treatment of diabetics and other diseases as an AMPK activator.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 14, 2019
    Assignees: CHANGZHOU DEZE MEDICAL SCIENCE CO., LTD
    Inventors: Houlei Teng, Wei Wu, Jingzhuo Zhang, Zhe Lin
  • Patent number: 10278948
    Abstract: A novel method for treating pain conditions, impulse control conditions, and also for treating obesity may include transnasally delivering topiramate or a pharmaceutical salt thereof to the sphenopalatine ganglion of a patient. This method of delivery will provide effective treatment of one or more of obesity, epileptic seizure, intracranial hypertension, glaucoma, altitude sickness, cystinuria, periodic paralysis, central sleep apnea, dural ectasia, fibromyalgia, neuropathic pain, central pain syndrome, nicotine addiction, alcohol addiction, cocaine addiction, and/or for enhancing or effecting cocaine-ingestion reduction, binge-eating reduction, and/or reduction of incidence of migraine headache onset, with an effective dosage amount that is a small fraction of known effective oral dosages.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: May 7, 2019
    Inventor: Tian Xia
  • Patent number: 10258647
    Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 16, 2019
    Assignee: PARTICLE DYNAMICS INTERNATIONAL, LLC
    Inventors: Paul Brady, Keith Cromack
  • Patent number: 10251904
    Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 9, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel
  • Patent number: 10253281
    Abstract: A method of washing textile articles can be carried out, for example, in a continuous batch tunnel washer. Embodiments of the present method can include treating the textile with an aqueous composition including cleaning agent and halogen-containing bleaching agent for a time sufficient to remove soil from the textile and contacting the halogen-treated textile with an aqueous composition including a peroxycarboxylic acid. The concentration of halogen after the sufficient time can be at a level that does not result in adverse interaction between the halogen-containing bleaching agent and the peroxycarboxylic acid. Embodiments of the present method can clean textiles with the results of more effective stain removal and less waste through destruction of the textile article. Further, the present invention can clean a textile contacted soiled by a composition including chlorhexidine gluconate without resulting staining of the textile, which staining could have been permanent.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: April 9, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Russell Shawn Berman, Max Donald Harper, Joel Monroe Madenwald, Carl Henry Mattson
  • Patent number: 10251898
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: April 9, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Byoung Kwon Chun, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
  • Patent number: 10245231
    Abstract: The present invention relates to a novel dry acid concentrate (DAC) for a dialysis liquid and to a dialysis liquid, which is made from said concentrate, and which may be used for purifying blood. The invention further relates to a method of making the dry acid concentrate as well as the dialysis liquid. It also relates to a container (10) comprising said acid concentrate, and which is—in certain embodiments—specially adapted to a dialysis unit.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 2, 2019
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventors: Thierry Eyrard, Philippe Laffay, Benoit Luaire
  • Patent number: 10246476
    Abstract: A method for producing high purity D-psicose crystals having a purity of 98% (w/w) or more and a grain size of MA200 or more. The method includes: removing impurities from a D-psicose solution to obtain a purified D-psicose solution; concentrating the purified D-psicose solution; cooling the concentrated D-psicose solution to 30° C. to 40° C. through a heat exchanger; seed crystallizing the D-psicose solution at 30° C. to 40° C. to obtain a seed crystallized massecuite; and full-scale crystallizing the seed crystallized massecuite. The method can produce pure D-psicose crystals in a suitable form for industrial application through an economical crystallization process from the D-psicose solution without using organic solvents.
    Type: Grant
    Filed: August 9, 2015
    Date of Patent: April 2, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Seong Bo Kim, Seung Won Park, Jun Gap An, Joo Hang Lee
  • Patent number: 10245277
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 2, 2019
    Assignees: VOLANT HOLDINGS GMBH, THERABRAKE, INC.
    Inventors: Joseph M. Fayad, Jerome Schentag
  • Patent number: 10242852
    Abstract: The invention relates to the detection of fatty acids. In a particular aspect, the invention relates to methods for detecting very long chain fatty acids and branched chain fatty acids by mass spectrometry.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 26, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Scott Goldman
  • Patent number: 10226439
    Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 12, 2019
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
  • Patent number: 10213452
    Abstract: The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: February 26, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Abelardo Isaac Aguilera Peralta, Manuel Lopez-Cabrera, Rafael Selgas Gutierrez, Sonja Steppan, Jutta Passlick-Deetjen
  • Patent number: 10202623
    Abstract: An object of the present invention is to provide a series of techniques for producing 1,4-butanediol from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding at least one enzyme selected from the group consisting of succinate semialdehyde dehydrogenase, succinyl-CoA synthase, CoA-dependent succinate semialdehyde dehydrogenase, 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryl-CoA reductase, 4-hydroxybutyraldehyde dehydrogenase, and alcohol dehydrogenase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing 1,4-butanediol from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: February 12, 2019
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventors: Masahiro Furutani, Akihiro Uenishi, Koichiro Iwasa
  • Patent number: 10201179
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 12, 2019
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 10195227
    Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 5, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10183053
    Abstract: Multi-component formulations comprise methylsulfonylmethane, fructose 1,6-diphosphate, and just one of trehalose, green tea extract, ashwagandha, and rutin, or a combination thereof. Multi-component formulations can prevent, delay, or treat cognitive decline, Alzheimer's disease, and other dementias.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 22, 2019
    Inventor: Gene S. Rosen
  • Patent number: 10183038
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 22, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10182998
    Abstract: The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharmaceutically acceptable excipient. The present disclosure further provides a method for treating MPE by using the pharmaceutical composition.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 22, 2019
    Assignee: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Mao-Yuan Lin
  • Patent number: 10174010
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms, which as compared to the prior art, have higher stability in water or aqueous system, are more suitable for wet granulation processes or suspension preparations and have good storage stability; the present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: January 8, 2019
    Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xiaoxia Sheng, Xiaohong Sheng, Kun Zhao, Xiaoye Song
  • Patent number: 10165792
    Abstract: The hunger minimized fasting system relies on providing a blood glucose level at all times in the range of 5 to 10 mM, satisfying glucose needs of the brain and metabolizing blood glucose through anaerobic glycolysis to release ATP at the extramitocontrial portion of the cell. Consuming only solid free nutrient liquids eliminates brain hunger response. Liquids consumed during fasting include solid filtered vegetable soup and clear fruit juices of 8 to 12 ounces taken every 2 to 4 hours having calorie deficiency of 600 to 1400 as compared to minimal daily calorie requirements for an adult. Fat released from storage is metabolized by ATP produced by glycolysis at the extramitocontrial location and enters the interior of the mitochondria, enabling the TCA cycle. Weight loss observed during fasting is about one half to one pound per day.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: January 1, 2019
    Inventors: Sudarshan Narasimhan, Dave Narasimhan
  • Patent number: 10117834
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 6, 2018
    Assignee: BIOGEN CHESAPEAKE LLC
    Inventor: Sven Jacobson
  • Patent number: 10092495
    Abstract: The invention concerns a use of C7 sugars and derivatives of formula (I), called avocado perseose, which have, inter alia, a protective activity to epidermal skin cells. These C7 sugars and derivatives are capable of maintaining the expression of markers of adult stem cells, in particular basal stem cells. Avocado perseose can also be used for preventing the deleterious effects of environmental damage. Avocado perseose has a beneficial effect on the conservation of the potential of epidermal stem cells and thus helps maintain skin homeostasis.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: October 9, 2018
    Assignee: LABORATOIRE EXPANSCIENCE
    Inventors: Philippe Msika, Caroline Baudouin
  • Patent number: 10093616
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: October 9, 2018
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • Patent number: 10076131
    Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: September 18, 2018
    Assignee: Nestec S.A.
    Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
  • Patent number: 10071032
    Abstract: Compositions and methods of treating and/or preventing conditions of the oral cavity, e.g. gingivitis, comprise applying a toothpaste composition comprising at least 5% sodium chloride in a toothpaste base comprising a zinc salt, non-silica calcium carbonate abrasive and humectant, to the oral surfaces, e.g., the teeth and gums, of a patient in need thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: September 11, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Yun Xu, Dorathy Zeng, Kahn Tan, Pingdong Li
  • Patent number: 10071057
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: September 11, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10039709
    Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: August 7, 2018
    Assignee: TRILOGIC PHARMA LLC
    Inventors: Hemant H. Alur, James A. H. Harwick, Mondal Pravakar, Thomas P. Johnston
  • Patent number: 10022389
    Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 17, 2018
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuke Yamamoto, Fusayo Io, Koji Yamamoto
  • Patent number: 10023600
    Abstract: Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: July 17, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Thomas Butler, Aesop Cho, Benjamin R. Graetz, Choung U. Kim, Samuel E. Metobo, Oliver L. Saunders, Andrew W. Waltman, Jie Xu, Lijun Zhang
  • Patent number: 9987222
    Abstract: The present invention relates to a method for the administration of a probiotic composition to a vaginal cavity and to compositions, devices and kits for use in this method.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: June 5, 2018
    Assignee: BIOSOMA B.V.
    Inventor: Floris Koumans
  • Patent number: 9969788
    Abstract: The present invention is directed to proteins in which a heparin binding peptide is fused to a growth factor that promotes cell growth and survival. The compound thus formed is bound to the surface of cells which are then administered to damaged tissue. The growth factor is thereby maintained at the site of administration where it promotes repair.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: May 15, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Richard Lee
  • Patent number: 9949997
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Patent number: 9949998
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Patent number: 9949996
    Abstract: The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 24, 2018
    Assignee: GRI BIO, INC.
    Inventor: Vipin Kumar Chaturvedi
  • Patent number: 9943098
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: December 26, 2016
    Date of Patent: April 17, 2018
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 9937125
    Abstract: The invention provides intradialytic parenteral nutrition (IDPN) solutions with low carbohydrate for the treatment of malnutrition in dialysis patients. The IDPN solutions of the invention are particularly advantageous for the treatment of malnutrition in patients who are diabetic or suffer from other glucose management related pathologies or patients who require strict fluid management.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 10, 2018
    Assignee: Pentec Health, Inc.
    Inventor: Eileen Moore
  • Patent number: 9918870
    Abstract: A method of treating snoring and/or OSA in a subject in need of such treatment. The method includes crosslinking proteins of the subject's soft palate tissue or pharynx tissue. The crosslinking can occur by contacting the soft palate or pharynx tissue with a crosslinking reagent. In addition, the crosslinking can occur without heating, contracting or denaturing of the tissue, or any combination thereof.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: March 20, 2018
    Assignee: Orthopeutics, L.P.
    Inventors: Thomas P. Hedman, Pawel Slusarewicz
  • Patent number: 9907848
    Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: March 6, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Mark A. Exley, Lydia Lynch, Donal O'Shea, Cliona O'Farrelly, Steven P. Balk
  • Patent number: 9895389
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • Patent number: 9884853
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: February 6, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Mitchell, Naomi Went
  • Patent number: 9873714
    Abstract: The present invention relates to processes for preparing a glucopyranosyl-substituted benzyl-benzene derivative of general formula III, wherein R1 is defined according to claim 1.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 23, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Weber, Tobias Fiedler, Christian Filser, Rainer Hamm, Simone Orlich, Matthias Post, Svenja Renner, Xiao-Jun Wang, Thomas Wirth
  • Patent number: 9861646
    Abstract: A dental composition comprising a therapeutically effective amount of doxycycline hyclate and a therapeutically effective amount of triamcinolone acetonide and use in dental treatment.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 9, 2018
    Assignee: OZDENT PTY LTD
    Inventor: Joshua George Tadros
  • Patent number: 9861575
    Abstract: A nutrition infusion is provided for administration through a peripheral vein that contains a vitamin B group and vitamin C stably and includes two solutions of a sugar solution and an amino acid solution. In the nutrition infusion for administration through a peripheral vein, the sugar solution contains vitamin B1, vitamin B12, and pantothenic acid and has a pH of 4.7 to 5.5, and the amino acid solution contains vitamin B2, folic acid, vitamin C, and biotin and has a pH of 7.0 to 7.5.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 9, 2018
    Assignee: EA Pharma Co., Ltd.
    Inventors: Kazuhiro Abiko, Toshiyuki Katsura
  • Patent number: 9854811
    Abstract: The present invention includes compositions and methods for the treatment of plants against pathogens, elimination of insects and to increase the shelf-life of fruits and vegetables that includes coating the plant with undiluted aloe vera gel.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: January 2, 2018
    Assignee: Coats Agri Aloe, LLC
    Inventor: Billy C. Coats
  • Patent number: 9849103
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 26, 2017
    Inventor: Young Hee Ko
  • Patent number: 9834573
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Theracos Sub, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Patent number: RE46762
    Abstract: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 27, 2018
    Assignee: GILEAD SCIENCES, INC
    Inventors: Thomas Butler, Aesop Cho, Choung U. Kim, Jay P. Parrish, Oliver L. Saunders, Lijun Zhang